

AMENDMENTS TO THE CLAIMS

1. (currently amended) A method of modulating an immune response comprising the step of administering a compound that is a competitive inhibitor of the ligand to TREM-1 to an animal to decrease myeloid cell activation, wherein said decrease comprises decreasing the activity of DAP12/TREM-1 complex.
2. canceled.
3. (currently amended) The method of claim 21, wherein said competitive inhibitor is a polypeptide comprising the amino acid sequence of SEQ.ID.NO:2.
4. (previously presented) The method of claim 31, wherein said inhibitor is a functional equivalent of the amino acid sequence of SEQ.ID.NO:2.
5. (previously presented) The method of claim 1, wherein said immune response is an inflammatory response.
6. (previously presented) The method of claim 1, wherein said compound increases the levels of TREM-1sv.
7. (currently amended) A method of decreasing myeloid cell activation comprising the step of administering to an animal a compound that is a competitive inhibitor of the ligand for TREM-1 to decrease the activity of DAP12/TREM-1 complex.
8. canceled
9. (currently amended) The method of claim 87, wherein said competitive inhibitor is a polypeptide comprising an amino acid sequence of SEQ.ID.NO:2.
10. (currently amended) The method of claim 87, wherein said competitive inhibitor is a functional equivalent of the polypeptide comprising an amino acid sequence of SEQ.ID.NO:2.
11. (currently amended) The method of claim 87, wherein said competitive inhibitor is admixed with a pharmaceutical carrier.

12. (currently amended) A method of modulating an inflammatory response in a subject suffering from a disease or condition, ~~wherein the disease or condition~~ that results in inflammation, said method comprising the step of altering the activity of the DAP12/TREM-1 complex.
13. (previously presented) The method of claim 12, wherein altering comprises modulating the binding of a ligand to TREM-1.
14. (previously presented) The method of claim 13, wherein modulating the binding comprises administering a competitive inhibitor for the ligand of TREM-1, wherein the competitive inhibitor is a polypeptide comprising SEQ.ID.NO:2 or a functional equivalent thereof.
15. (previously presented) The method of claim 12, wherein the disease or condition is selected from the group consisting of organ transplant/rejection, bone marrow transplant/rejection, graft versus host disease, infectious disease, autoimmune diseases.
16. (previously presented) The method of claim 15, wherein the infectious disease is septic arthritis or septic shock.
17. (previously presented) The method of claim 13, wherein modulating the binding comprises administering a compound that increases the levels of TREM-1sv, wherein TREM-1sv is a competitive inhibitor for the ligand of TREM-1.